Latteno's Subsidiary Green Cannabis Introduces Medical Marijuana Edible Products
Company's Growth and Expansion Allows Immediate Access to Funding and Exclusive Partnership
PR Newswire
SANTA ANA, Calif., May 14, 2013
SANTA ANA, Calif. , May 14, 2013 /PRNewswire/ -- Latteno Food Corp.'s (OTCPink: LATF) wholly-owned subsidiary Green Cannabis, today announced the release of new roll-out medical marijuana edible products consisting of our own private label Peanut Butter Cup, Chocolate Bar and Chocolate Chip Cookie all made out of Cannabutter. These are Endocannabinoid CBD Edibles:
Peanut Butter Cups consist 200mg of THC, Indica
Chocolate Bars contain a full gram of hash
Chocolate Chip Cookies contain 105THC, 1.3 CBD and 1.1 CBN
The endocannabinoid system refers to a group of neuromodulatory lipids and their receptors that are involved in a variety of physiological processes including appetite, pain-sensation, mood, and memory; it mediates the psychoactive effects of cannabis and, broadly speaking, includes:
- The endogenous arachidonate-based lipids, anandamide (N-arachidonoylethanolamide, AEA) and 2-arachidonoylglycerol (2-AG); these are known as "endocannabinoids" and are physiological ligands for the cannabinoid receptors. Endocannabinoids are all eicosanoids.
- The enzymes that synthesize and degrade the endocannabinoids, such as fatty acid amide hydrolase or monoacylglycerol lipase.
- The cannabinoid receptors CB1 and CB2, two G protein-coupled receptors that are located in the central and peripheral nervous systems.
The endocannabinoid system has been studied using genetic and pharmacological methods. These studies have revealed that cannabinoids act as neuromodulators for a variety of physiological processes, including motor learning, synaptic plasticity, appetite, and pain sensation.
Potential Benefits:
Anti-inflammatory refers to the property of a substance or treatment that reduces inflammation. Anti-inflammatory drugs make up about half of analgesics, remedying pain by reducing inflammation as opposed to opioids, which affect the central nervous system.
Antimitogenic: the effect of a chemical substance that inhibits cell division. To stop cancer cell from multiplying.
Antiangiogenic: the effect of a chemical substance that inhibits the growth of new blood vessels.
Proapototic: encourage the process of programmed cell death (PCD) that may occur in multicellular organisms.
Research has shown that eating instead of smoking is far more beneficial for most patients.
For full products description, please visit green-cannabis.com.
The Company has moved quickly with the implementation of its new initiatives through strategic acquisitions, innovative product development projects and tactical licensing arrangements and has substantially grown and strengthened its revenue projections and asset valuation. Also, Latteno has been approached by several small cap hedge funds and boutique investment houses about a near term private placement and cash infusion to fund its growth and acquisitions.
"We are pleased to roll out our first initial medical marijuana edible products. We have other products in line for immediate release once approved by our doctors and research scientists," stated Thu Le, Chief Executive Officer. "Our goal and objective is to regularly introducing safe and healthy products that would greatly benefit our co-op patients and partners."
About Latteno Food Corp. ( www.Latteno.com )
Latteno Food Corp. is an investment portfolio company that acquires food products, medical marijuana edibles and related products/services to enhance their growth and development. The company builds revenues and asset value through a model of continuous growth, income from or sale of its portfolio holdings, and product licensing or distribution agreements.
About Green Cannabis Collective Inc. ( www.Green-Cannabis.com )
A Southern California-owned and licensed medical marijuana dispensary and transporting. The specific purpose of this corporation is to collectively facilitate medical marijuana cultivation and transactions by and between qualified patient members of this corporation and/or primary caregiver members who have the oral or written approval or recommendation of a licensed physician, as permitted and authorized by the Compassionate Use Act of 1996 (Health and Safety Code section 11362.5) and the Medical Marijuana Program Act (Health and Safety Code sections 11362.7 – 11362.83).
Safe Harbor Statement
This release contains forward-looking statements within the meaning of Section 27a of the Securities Act of 1933, as amended and section 21e of the Securities and Exchange Act of 1934, as amended. Those statements include the intent, belief or current expectations of the company and its management team. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. Accomplishing the strategy described herein is significantly dependent upon numerous factors, many that are not in management's control. Some of these factors include the ability of the company to raise sufficient capital, attract qualified management, attract new customers and effectively compete against similar companies.
Contact: Investor Relations (714) 426-2955
info@latteno.com
SOURCE Latteno Food Corp.
